Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06632600 · ClinicalTrials.gov registry record · Phase 2
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
A Phase 2 study of Chagas Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 18
- Study locations
NCT06632600: Recruiting Phase 2 study of Chagas Disease, sponsored by Novartis Pharmaceuticals.
NCT06632600 is a Phase 2 study of Chagas Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 130 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06632600, a Phase 2 study of Chagas Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.
Primary Outcome
The parasitological load will be measured using polymerase chain reaction (PCR) at 2 months, 4 months, and at 6 months. At each timepoint, multiple samples are evaluated. The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all 3 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LXE408
- DRUG Benznidazole
Study Locations (18)
Other
- Novartis Investigative Site - Corrientes
- Novartis Investigative Site - Córdoba
- Novartis Investigative Site - Formosa
- Novartis Investigative Site - Bogotá
- Novartis Investigative Site - Bogotá
- Novartis Investigative Site - Floridablanca
- Novartis Investigative Site - San Gil
Buenos Aires
- Novartis Investigative Site - CABA
- Novartis Investigative Site - CABA
California
- Olive View UCLA Educ and Res Ins - Sylmar
Florida
- University of Florida Shands - Gainesville
Massachusetts
- Boston Medical Center - Boston
Texas
- Baylor College of Medicine - Houston
Minas Gerais
- Novartis Investigative Site - Montes Claros
Rio de Janeiro
- Novartis Investigative Site - Rio de Janeiro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2030-09-21 |
| Phase | Phase 2 |
What NCT06632600 shows while recruiting
NCT06632600 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Chagas Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06632600 lists 18 locations in 11 states (Other, Buenos Aires, California).
Frequently Asked Questions
What is clinical trial NCT06632600 about?
NCT06632600 is a clinical study titled "A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.". This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.
What is the current status of trial NCT06632600?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2025-04-28. Estimated completion is 2030-09-21.
What conditions does trial NCT06632600 study?
This clinical trial studies the following conditions: Chagas Disease.
What interventions are being tested in trial NCT06632600?
The interventions under investigation include: Placebo (DRUG), LXE408 (DRUG), Benznidazole (DRUG).
Who is sponsoring clinical trial NCT06632600?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06632600 being conducted?
This trial has 18 study locations across California, Florida, Massachusetts, Texas, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chagas Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06632600's enrollment target sits among peer trials
130 543rd of 2000 higher than 1,448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI